Dr. Reddy's Laboratories Key Executives
This section highlights Dr. Reddy's Laboratories's key executives, including their titles and compensation details.
Find Contacts at Dr. Reddy's Laboratories
(Showing 0 of )
Dr. Reddy's Laboratories Earnings
This section highlights Dr. Reddy's Laboratories's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2025 | 2025-01-23 | N/A | N/A |
| Read Transcript | Q2 | 2025 | 2024-11-05 | $0.04 | $0.04 |
| Read Transcript | Q4 | 2024 | 2024-05-07 | $0.17 | $0.19 |
| Read Transcript | Q3 | 2024 | 2024-01-30 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2023-10-27 | $0.18 | $0.21 |
| Read Transcript | Q1 | 2024 | 2023-07-26 | $0.14 | $0.21 |
| Read Transcript | Q4 | 2023 | 2023-05-11 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-01-25 | $0.12 | $0.18 |
| Read Transcript | Q2 | 2023 | 2022-10-28 | $0.12 | $0.16 |
| Read Transcript | Q1 | 2023 | 2022-07-31 | N/A | N/A |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
$13.20
Stock Price
$11.00B
Market Cap
27.05K
Employees
Hyderabad, None
Location
Financial Statements
Access annual & quarterly financial statements for Dr. Reddy's Laboratories, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $279.16B | $245.88B | $214.39B | $189.72B | $174.60B |
| Cost of Revenue | $115.56B | $42.91B | $100.55B | $86.64B | $80.59B |
| Gross Profit | $163.61B | $202.97B | $113.84B | $103.08B | $94.01B |
| Gross Profit Ratio | 58.60% | 82.50% | 53.10% | 54.30% | 53.84% |
| Research and Development Expenses | $22.87B | $19.38B | $17.48B | $16.54B | $15.41B |
| General and Administrative Expenses | $- | $46.47B | $- | $- | $- |
| Selling and Marketing Expenses | $- | $59.47B | $- | $- | $- |
| Selling General and Administrative Expenses | $77.20B | $105.93B | $62.08B | $54.56B | $50.13B |
| Other Expenses | $-4.20B | $-7.70B | $-2.76B | $-982.00M | $-4.29B |
| Operating Expenses | $95.88B | $117.61B | $76.80B | $70.12B | $61.25B |
| Cost and Expenses | $211.44B | $160.52B | $177.35B | $156.76B | $141.84B |
| Interest Income | $2.28B | $1.18B | $3.08B | $2.62B | $888.00M |
| Interest Expense | $1.71B | $1.43B | $958.00M | $970.00M | $983.00M |
| Depreciation and Amortization | $14.84B | $12.64B | $11.82B | $12.80B | $12.47B |
| EBITDA | $88.42B | $74.43B | $47.74B | $45.71B | $41.78B |
| EBITDA Ratio | 31.67% | 44.24% | 24.55% | 25.75% | 28.37% |
| Operating Income | $67.73B | $96.28B | $40.82B | $36.06B | $37.05B |
| Operating Income Ratio | 24.26% | 39.16% | 19.04% | 19.01% | 21.22% |
| Total Other Income Expenses Net | $4.14B | $3.34B | $2.82B | $4.04B | $2.04B |
| Income Before Tax | $71.87B | $60.48B | $32.30B | $28.32B | $18.03B |
| Income Before Tax Ratio | 25.74% | 24.60% | 15.06% | 14.93% | 10.33% |
| Income Tax Expense | $16.19B | $15.41B | $8.73B | $9.18B | $-1.47B |
| Net Income | $55.68B | $45.07B | $23.57B | $17.24B | $19.50B |
| Net Income Ratio | 19.95% | 18.33% | 10.99% | 9.09% | 11.17% |
| EPS | $66.80 | $54.29 | $28.42 | $20.79 | $23.53 |
| EPS Diluted | $66.80 | $54.17 | $28.34 | $20.73 | $23.48 |
| Weighted Average Shares Outstanding | 833.54M | 830.17M | 829.41M | 829.22M | 828.79M |
| Weighted Average Shares Outstanding Diluted | 833.54M | 831.91M | 831.69M | 831.58M | 830.41M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.59B | $80.16B | $76.73B | $70.83B | $72.15B | $68.80B | $67.38B | $62.97B | $67.70B | $63.06B | $52.15B | $54.37B | $53.20B | $57.63B | $49.19B | $47.28B | $49.30B | $48.97B | $44.17B | $44.32B |
| Cost of Revenue | $34.53B | $32.39B | $30.38B | $29.35B | $29.95B | $28.43B | $27.83B | $11.31B | $27.61B | $25.81B | $26.15B | $25.62B | $24.59B | $26.85B | $23.50B | $21.91B | $22.76B | $22.56B | $19.42B | $21.51B |
| Gross Profit | $49.05B | $47.77B | $46.34B | $41.48B | $42.20B | $40.37B | $39.55B | $51.66B | $40.09B | $37.25B | $26.01B | $28.74B | $28.61B | $30.79B | $25.70B | $25.38B | $26.54B | $26.41B | $24.75B | $22.81B |
| Gross Profit Ratio | 58.68% | 59.60% | 60.40% | 58.60% | 58.50% | 58.70% | 58.70% | 82.00% | 59.20% | 59.10% | 49.90% | 52.90% | 53.80% | 53.40% | 52.20% | 53.70% | 53.80% | 53.90% | 56.00% | 51.46% |
| Research and Development Expenses | $6.66B | $7.27B | $6.19B | $6.88B | $5.57B | $5.45B | $4.98B | $5.37B | $4.82B | $4.87B | $4.33B | $4.33B | $4.16B | $4.46B | $4.53B | $4.09B | $4.11B | $4.36B | $3.98B | $4.19B |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $12.76B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $15.53B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $24.12B | $23.01B | $22.69B | $20.48B | $20.23B | $18.80B | $17.70B | $28.29B | $17.98B | $16.56B | $15.49B | $15.67B | $15.41B | $15.95B | $15.04B | $14.28B | $14.39B | $13.11B | $12.79B | $12.18B |
| Other Expenses | $-443.00M | $-60.00M | $-465.00M | $- | $- | $- | $- | $-2.39B | $800.00M | $-423.00M | $-6.00B | $-291.00M | $-215.00M | $-612.00M | $-458.00M | $-591.00M | $-151.00M | $-163.00M | $-119.00M | $-242.00M |
| Operating Expenses | $30.33B | $30.22B | $28.42B | $26.49B | $25.30B | $22.88B | $21.91B | $31.26B | $23.60B | $21.01B | $13.81B | $19.71B | $19.36B | $19.80B | $19.12B | $17.79B | $18.37B | $17.32B | $16.65B | $16.20B |
| Cost and Expenses | $64.87B | $62.61B | $58.80B | $55.84B | $55.24B | $51.32B | $49.74B | $42.58B | $51.21B | $46.82B | $39.96B | $45.33B | $43.94B | $46.65B | $42.62B | $39.70B | $41.12B | $39.88B | $36.07B | $37.71B |
| Interest Income | $704.00M | $665.00M | $- | $647.00M | $583.00M | $719.00M | $329.00M | $474.00M | $2.69B | $216.00M | $217.00M | $1.18B | $262.00M | $237.00M | $209.00M | $615.00M | $681.00M | $237.00M | $281.00M | $181.00M |
| Interest Expense | $818.00M | $757.00M | $- | $593.00M | $394.00M | $353.00M | $371.00M | $354.00M | $419.00M | $309.00M | $347.00M | $316.00M | $215.00M | $234.00M | $193.00M | $297.00M | $188.00M | $252.00M | $233.00M | $230.00M |
| Depreciation and Amortization | $4.72B | $3.98B | $3.81B | $3.71B | $3.77B | $3.79B | $3.57B | $3.19B | $3.27B | $3.13B | $3.05B | $2.96B | $2.98B | $2.98B | $2.90B | $3.17B | $3.22B | $3.27B | $3.14B | $2.96B |
| EBITDA | $24.28B | $23.90B | $21.76B | $18.50B | $21.62B | $20.29B | $21.22B | $16.80B | $18.83B | $19.37B | $9.60B | $11.99B | $12.28B | $13.97B | $9.48B | $9.63B | $11.41B | $12.38B | $11.25B | $10.34B |
| EBITDA Ratio | 29.05% | 29.81% | 28.36% | 26.12% | 29.50% | 32.03% | 26.21% | 39.71% | 28.43% | 31.28% | 29.82% | 18.97% | 23.84% | 25.08% | 20.04% | 17.73% | 18.26% | 20.16% | 26.27% | 14.93% |
| Operating Income | $18.72B | $17.55B | $17.93B | $14.79B | $17.27B | $17.87B | $17.64B | $21.95B | $16.43B | $16.13B | $12.21B | $7.36B | $9.23B | $12.12B | $6.61B | $7.57B | $2.20B | $8.31B | $8.11B | $6.60B |
| Operating Income Ratio | 22.40% | 21.89% | 23.36% | 20.88% | 23.93% | 25.97% | 26.17% | 34.86% | 24.26% | 25.58% | 23.42% | 13.53% | 17.36% | 21.02% | 13.43% | 16.02% | 4.46% | 16.97% | 18.35% | 14.90% |
| Total Other Income Expenses Net | $22.00M | $1.62B | $896.00M | $1.06B | $990.00M | $1.27B | $827.00M | $911.00M | $-79.00M | $-16.00M | $2.44B | $-4.87B | $474.00M | $566.00M | $818.00M | $2.41B | $644.00M | $310.00M | $682.00M | $540.00M |
| Income Before Tax | $18.74B | $19.17B | $18.82B | $16.02B | $18.26B | $19.13B | $18.46B | $13.29B | $16.35B | $16.11B | $14.65B | $2.48B | $9.71B | $12.68B | $7.42B | $8.07B | $2.84B | $8.62B | $8.79B | $7.14B |
| Income Before Tax Ratio | 22.42% | 23.91% | 24.53% | 22.61% | 25.30% | 27.81% | 27.40% | 21.11% | 24.14% | 25.55% | 28.10% | 4.57% | 18.25% | 22.00% | 15.09% | 17.07% | 5.77% | 17.61% | 19.90% | 16.12% |
| Income Tax Expense | $4.70B | $5.75B | $4.90B | $2.95B | $4.47B | $4.33B | $4.44B | $3.69B | $3.88B | $4.98B | $2.78B | $1.61B | $2.64B | $2.76B | $1.72B | $2.54B | $2.65B | $998.00M | $3.00B | $-500.00M |
| Net Income | $14.13B | $12.55B | $13.92B | $13.07B | $13.79B | $14.80B | $14.03B | $9.59B | $12.47B | $11.13B | $11.88B | $875.00M | $7.07B | $9.92B | $5.71B | $5.54B | $198.00M | $7.62B | $5.79B | $7.64B |
| Net Income Ratio | 16.91% | 15.66% | 18.14% | 18.45% | 19.11% | 21.51% | 20.81% | 15.23% | 18.42% | 17.65% | 22.77% | 1.61% | 13.28% | 17.21% | 11.60% | 11.71% | 0.40% | 15.57% | 13.11% | 17.24% |
| EPS | $16.96 | $15.06 | $16.69 | $15.70 | $16.56 | $17.79 | $16.88 | $11.55 | $15.02 | $13.48 | $14.31 | $1.05 | $8.52 | $11.96 | $6.89 | $6.68 | $0.24 | $9.19 | $6.99 | $9.22 |
| EPS Diluted | $16.94 | $15.05 | $16.69 | $15.67 | $16.54 | $17.76 | $16.84 | $11.53 | $14.99 | $13.38 | $14.28 | $1.05 | $8.50 | $11.93 | $6.87 | $6.66 | $0.24 | $9.17 | $6.97 | $9.20 |
| Weighted Average Shares Outstanding | 833.31M | 833.62M | 833.93M | 832.57M | 832.57M | 831.83M | 830.86M | 830.68M | 830.40M | 825.52M | 829.79M | 829.79M | 829.61M | 829.43M | 828.69M | 829.09M | 831.93M | 829.31M | 828.99M | 828.88M |
| Weighted Average Shares Outstanding Diluted | 834.30M | 834.11M | 833.93M | 833.95M | 833.88M | 833.52M | 832.78M | 832.26M | 831.81M | 831.81M | 831.65M | 831.75M | 831.57M | 831.52M | 831.10M | 831.33M | 831.93M | 831.66M | 830.90M | 830.47M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.11B | $5.78B | $14.85B | $14.83B | $2.05B |
| Short Term Investments | $74.36B | $60.97B | $29.51B | $19.74B | $23.69B |
| Cash and Short Term Investments | $81.47B | $66.75B | $44.37B | $34.57B | $25.74B |
| Net Receivables | $80.30B | $72.48B | $66.76B | $49.64B | $50.28B |
| Inventory | $63.55B | $48.67B | $50.88B | $45.41B | $35.07B |
| Other Current Assets | $22.73B | $21.30B | $19.84B | $18.62B | $19.29B |
| Total Current Assets | $248.05B | $204.25B | $181.11B | $148.25B | $130.37B |
| Property Plant Equipment Net | $76.89B | $56.54B | $62.17B | $57.11B | $52.33B |
| Goodwill | $4.25B | $5.47B | $4.42B | $4.57B | $3.99B |
| Intangible Assets | $36.95B | $30.72B | $27.25B | $35.65B | $27.66B |
| Goodwill and Intangible Assets | $41.20B | $36.20B | $31.66B | $40.22B | $31.65B |
| Long Term Investments | $5.25B | $6.09B | $7.99B | $8.33B | $3.09B |
| Tax Assets | $- | $7.05B | $12.78B | $10.63B | $12.21B |
| Other Non-Current Assets | $16.12B | $12.71B | $948.00M | $952.00M | $2.58B |
| Total Non-Current Assets | $139.47B | $118.60B | $115.55B | $117.24B | $101.87B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $387.52B | $322.85B | $296.65B | $265.49B | $232.24B |
| Account Payables | $21.55B | $17.86B | $15.97B | $12.70B | $10.74B |
| Short Term Debt | $14.03B | $12.19B | $28.10B | $24.01B | $20.80B |
| Tax Payables | $2.34B | $2.14B | $5.44B | $1.39B | $573.00M |
| Deferred Revenue | $- | $1.98B | $2.58B | $2.03B | $1.91B |
| Other Current Liabilities | $58.12B | $53.53B | $48.33B | $45.30B | $40.70B |
| Total Current Liabilities | $96.04B | $85.72B | $97.84B | $81.47B | $72.81B |
| Long Term Debt | $5.99B | $1.28B | $5.75B | $6.30B | $1.30B |
| Deferred Revenue Non-Current | $- | $1.55B | $1.60B | $1.53B | $1.96B |
| Deferred Tax Liabilities Non-Current | $- | $760.00M | $60.00M | $338.00M | $275.00M |
| Other Non-Current Liabilities | $4.94B | $2.99B | $2.54B | $2.40B | $3.13B |
| Total Non-Current Liabilities | $10.93B | $4.27B | $8.29B | $9.04B | $4.44B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $106.97B | $89.99B | $106.13B | $90.51B | $77.25B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $834.00M | $833.00M | $832.00M | $832.00M | $831.00M |
| Retained Earnings | $265.26B | $215.59B | $175.71B | $157.93B | $144.25B |
| Accumulated Other Comprehensive Income Loss | $4.03B | $1.27B | $1.06B | $1.33B | $2.42B |
| Other Total Stockholders Equity | $10.43B | $10.29B | $8.43B | $8.25B | $7.49B |
| Total Stockholders Equity | $280.55B | $232.86B | $190.53B | $174.98B | $154.99B |
| Total Equity | $280.55B | $232.86B | $190.53B | $174.98B | $154.99B |
| Total Liabilities and Stockholders Equity | $387.52B | $322.85B | $296.65B | $265.49B | $232.24B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $387.52B | $322.85B | $296.65B | $265.49B | $232.24B |
| Total Investments | $79.62B | $67.06B | $37.50B | $28.08B | $26.78B |
| Total Debt | $20.02B | $13.47B | $33.84B | $30.31B | $22.10B |
| Net Debt | $12.91B | $7.69B | $18.99B | $15.48B | $20.05B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $12.29B | $11.33B | $4.91B | $7.11B | $7.34B | $13.39B | $6.02B | $5.78B | $6.26B | $9.10B | $6.02B | $14.85B | $21.98B | $9.98B | $8.17B | $14.83B | $4.32B | $3.89B | $4.40B | $2.05B |
| Short Term Investments | $46.89B | $51.74B | $89.71B | $74.36B | $65.02B | $54.39B | $53.03B | $60.97B | $42.24B | $18.48B | $28.32B | $29.51B | $13.22B | $14.60B | $20.33B | $19.74B | $11.53B | $21.15B | $23.29B | $23.69B |
| Cash and Short Term Investments | $59.18B | $63.07B | $94.63B | $81.47B | $72.36B | $67.78B | $61.16B | $66.75B | $50.16B | $27.57B | $34.34B | $44.37B | $35.20B | $24.58B | $28.50B | $34.57B | $15.85B | $25.04B | $27.69B | $25.74B |
| Net Receivables | $111.49B | $102.84B | $81.09B | $80.30B | $96.08B | $89.69B | $77.09B | $72.48B | $75.05B | $76.99B | $73.21B | $66.76B | $62.45B | $68.61B | $61.02B | $49.64B | $53.16B | $50.08B | $46.57B | $50.28B |
| Inventory | $71.63B | $72.04B | $68.57B | $63.55B | $60.80B | $56.59B | $52.40B | $48.67B | $49.33B | $49.04B | $51.81B | $50.88B | $49.67B | $49.70B | $50.77B | $45.41B | $44.31B | $41.13B | $39.15B | $35.07B |
| Other Current Assets | $10.71B | $10.18B | $24.91B | $22.73B | $26.71B | $23.45B | $20.51B | $21.30B | $21.61B | $22.00B | $20.06B | $19.84B | $19.51B | $20.38B | $18.48B | $18.62B | $20.09B | $18.75B | $19.53B | $19.29B |
| Total Current Assets | $253.02B | $248.13B | $269.19B | $248.05B | $238.48B | $217.69B | $113.56B | $204.25B | $49.33B | $175.61B | $179.71B | $181.11B | $166.83B | $163.27B | $158.78B | $148.25B | $133.42B | $135.01B | $132.94B | $130.37B |
| Property Plant Equipment Net | $93.05B | $86.69B | $80.34B | $76.89B | $72.80B | $70.48B | $67.21B | $56.54B | $65.00B | $63.82B | $63.83B | $62.17B | $62.97B | $60.23B | $58.64B | $57.11B | $56.26B | $55.03B | $54.18B | $52.33B |
| Goodwill | $11.86B | $11.77B | $4.24B | $4.25B | $4.29B | $4.22B | $4.24B | $5.47B | $4.50B | $4.33B | $4.38B | $4.42B | $4.55B | $4.58B | $4.62B | $4.57B | $4.63B | $4.58B | $4.82B | $3.99B |
| Intangible Assets | $92.92B | $92.12B | $37.13B | $36.95B | $36.91B | $37.05B | $38.07B | $30.72B | $30.91B | $31.76B | $31.83B | $27.25B | $32.03B | $32.63B | $35.13B | $35.65B | $36.43B | $40.97B | $41.17B | $27.66B |
| Goodwill and Intangible Assets | $104.78B | $103.89B | $41.37B | $41.20B | $41.19B | $41.28B | $42.31B | $36.20B | $35.40B | $36.08B | $36.21B | $31.66B | $36.58B | $37.21B | $39.75B | $40.22B | $41.06B | $45.55B | $45.99B | $31.65B |
| Long Term Investments | $9.02B | $5.98B | $5.21B | $5.25B | $8.33B | $5.92B | $4.90B | $6.09B | $6.28B | $6.11B | $5.21B | $7.99B | $6.49B | $7.49B | $9.50B | $8.33B | $8.63B | $3.99B | $3.39B | $3.09B |
| Tax Assets | $18.27B | $17.48B | $- | $10.77B | $10.92B | $10.84B | $9.54B | $7.05B | $6.31B | $7.56B | $9.14B | $12.78B | $8.63B | $9.42B | $10.59B | $10.63B | $11.84B | $12.66B | $12.19B | $12.21B |
| Other Non-Current Assets | $2.92B | $3.79B | $19.18B | $5.35B | $1.13B | $812.00M | $-14.45B | $12.71B | $-12.59B | $1.80B | $1.88B | $948.00M | $999.00M | $882.00M | $968.00M | $952.00M | $1.13B | $1.14B | $2.55B | $2.58B |
| Total Non-Current Assets | $228.04B | $217.83B | $146.11B | $139.47B | $134.37B | $129.33B | $109.51B | $118.60B | $100.40B | $115.37B | $116.27B | $115.55B | $115.67B | $115.23B | $119.44B | $117.24B | $118.93B | $118.37B | $118.31B | $101.87B |
| Other Assets | $- | $- | $- | $- | $- | $- | $111.97B | $- | $159.58B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $481.06B | $465.95B | $415.30B | $387.52B | $372.84B | $347.02B | $335.04B | $322.85B | $309.30B | $290.97B | $295.98B | $296.65B | $282.50B | $278.50B | $278.21B | $265.49B | $252.35B | $253.38B | $251.24B | $232.24B |
| Account Payables | $36.02B | $35.78B | $34.11B | $21.55B | $31.11B | $30.48B | $27.68B | $17.86B | $26.02B | $22.78B | $25.05B | $15.97B | $24.49B | $25.55B | $28.61B | $12.70B | $23.07B | $22.83B | $19.04B | $10.74B |
| Short Term Debt | $43.51B | $41.18B | $24.45B | $14.03B | $13.70B | $7.19B | $7.59B | $12.19B | $16.21B | $15.49B | $22.76B | $28.10B | $22.13B | $24.30B | $27.21B | $24.01B | $13.94B | $20.77B | $24.79B | $20.80B |
| Tax Payables | $3.00B | $5.09B | $4.86B | $2.34B | $4.17B | $3.98B | $4.43B | $2.14B | $1.33B | $1.26B | $1.78B | $5.44B | $1.59B | $1.31B | $1.36B | $1.39B | $1.52B | $1.16B | $869.00M | $573.00M |
| Deferred Revenue | $2.00B | $1.53B | $10.33B | $1.44B | $2.27B | $3.00B | $47.77B | $1.98B | $- | $- | $- | $2.58B | $5.60B | $5.05B | $4.84B | $2.03B | $5.33B | $5.04B | $4.76B | $1.91B |
| Other Current Liabilities | $47.42B | $45.73B | $21.60B | $58.12B | $44.61B | $42.53B | $41.06B | $53.53B | $-17.54B | $40.50B | $41.19B | $48.33B | $24.25B | $24.63B | $24.67B | $43.38B | $24.68B | $23.73B | $25.66B | $40.70B |
| Total Current Liabilities | $131.95B | $129.30B | $105.67B | $96.04B | $93.60B | $84.18B | $55.36B | $85.72B | $26.02B | $80.03B | $90.79B | $97.84B | $83.65B | $85.90B | $91.53B | $81.47B | $73.87B | $78.57B | $79.88B | $72.81B |
| Long Term Debt | $7.58B | $7.36B | $6.23B | $5.99B | $6.15B | $6.04B | $4.93B | $1.28B | $1.46B | $1.79B | $1.90B | $5.75B | $6.03B | $5.98B | $6.17B | $6.30B | $6.51B | $6.66B | $6.79B | $1.30B |
| Deferred Revenue Non-Current | $905.00M | $999.00M | $61.00M | $1.19B | $1.44B | $1.50B | $60.00M | $1.55B | $- | $- | $- | $1.60B | $58.00M | $58.00M | $59.00M | $1.53B | $58.00M | $55.00M | $54.00M | $1.96B |
| Deferred Tax Liabilities Non-Current | $13.90B | $13.83B | $-61.00M | $909.00M | $989.00M | $102.00M | $642.00M | $760.00M | $160.00M | $46.00M | $55.00M | $60.00M | $108.00M | $99.00M | $67.00M | $338.00M | $99.00M | $206.00M | $216.00M | $275.00M |
| Other Non-Current Liabilities | $5.16B | $5.18B | $8.71B | $4.94B | $5.24B | $3.71B | $4.02B | $2.99B | $24.57B | $2.92B | $2.89B | $2.54B | $2.74B | $2.63B | $2.35B | $2.74B | $2.51B | $2.75B | $2.77B | $3.13B |
| Total Non-Current Liabilities | $27.54B | $27.37B | $15.00B | $10.93B | $11.39B | $9.75B | $9.01B | $4.27B | $26.02B | $4.72B | $4.79B | $8.29B | $8.83B | $8.67B | $8.57B | $9.04B | $9.08B | $9.47B | $9.61B | $4.44B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $-9.01B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $159.49B | $156.67B | $120.67B | $106.97B | $104.99B | $93.94B | $55.36B | $89.99B | $52.05B | $84.75B | $95.59B | $106.13B | $92.48B | $94.57B | $100.10B | $90.51B | $82.95B | $88.04B | $89.50B | $77.25B |
| Preferred Stock | $- | $- | $4.11B | $4.03B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $8.00M | $- | $- | $- | $- |
| Common Stock | $834.00M | $834.00M | $834.00M | $834.00M | $834.00M | $834.00M | $833.00M | $833.00M | $833.00M | $832.00M | $832.00M | $832.00M | $833.00M | $832.00M | $832.00M | $832.00M | $831.00M | $831.00M | $831.00M | $831.00M |
| Retained Earnings | $299.35B | $285.18B | $279.83B | $265.26B | $252.08B | $238.23B | $230.02B | $215.59B | $206.71B | $194.16B | $187.81B | $175.71B | $174.91B | $167.82B | $161.76B | $157.93B | $152.19B | $152.46B | $150.04B | $144.25B |
| Accumulated Other Comprehensive Income Loss | $4.48B | $4.52B | $4.11B | $653.00M | $762.00M | $810.00M | $864.00M | $1.27B | $553.00M | $631.00M | $833.00M | $1.06B | $982.00M | $1.01B | $1.30B | $1.33B | $1.53B | $1.06B | $3.14B | $-63.31B |
| Other Total Stockholders Equity | $13.05B | $14.81B | $1.63B | $1.71B | $9.71B | $9.60B | $8.63B | $10.29B | $8.18B | $7.90B | $8.31B | $8.43B | $7.64B | $7.54B | $7.27B | $9.57B | $7.89B | $7.74B | $7.74B | $7.49B |
| Total Stockholders Equity | $317.72B | $305.34B | $294.63B | $280.55B | $267.85B | $253.09B | $245.26B | $232.86B | $220.27B | $206.22B | $200.39B | $190.53B | $190.02B | $183.93B | $178.11B | $174.98B | $169.40B | $165.34B | $161.75B | $154.99B |
| Total Equity | $321.56B | $309.28B | $294.63B | $280.55B | $267.85B | $253.09B | $245.26B | $232.86B | $220.27B | $206.22B | $200.39B | $190.53B | $190.02B | $183.93B | $178.11B | $174.98B | $169.40B | $165.34B | $161.75B | $154.99B |
| Total Liabilities and Stockholders Equity | $481.06B | $465.95B | $415.30B | $387.52B | $372.84B | $347.02B | $335.04B | $322.85B | $309.30B | $290.97B | $295.98B | $296.65B | $282.50B | $278.50B | $278.21B | $265.49B | $252.35B | $253.38B | $251.24B | $232.24B |
| Minority Interest | $3.84B | $3.94B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $481.06B | $465.95B | $415.30B | $387.52B | $372.84B | $347.02B | $335.04B | $322.85B | $309.30B | $290.97B | $295.98B | $296.65B | $282.50B | $278.50B | $278.21B | $265.49B | $252.35B | $253.38B | $251.24B | $232.24B |
| Total Investments | $55.91B | $57.72B | $94.92B | $79.62B | $73.35B | $60.31B | $57.94B | $67.06B | $48.52B | $24.59B | $33.54B | $37.50B | $19.71B | $22.09B | $29.83B | $28.08B | $20.16B | $25.15B | $26.68B | $26.78B |
| Total Debt | $51.09B | $48.54B | $30.68B | $20.02B | $19.85B | $13.23B | $12.52B | $13.47B | $17.66B | $17.29B | $24.67B | $33.84B | $28.16B | $30.27B | $33.37B | $30.31B | $20.44B | $27.43B | $31.58B | $22.10B |
| Net Debt | $38.80B | $37.21B | $25.76B | $12.91B | $12.51B | $-161.00M | $6.50B | $7.69B | $11.40B | $8.19B | $18.65B | $18.99B | $6.19B | $20.29B | $25.20B | $15.48B | $16.12B | $23.54B | $27.18B | $20.05B |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $55.68B | $60.48B | $23.57B | $19.15B | $19.50B |
| Depreciation and Amortization | $14.84B | $12.50B | $11.82B | $12.80B | $12.47B |
| Deferred Income Tax | $16.19B | $15.30B | $8.73B | $9.18B | $-1.47B |
| Stock Based Compensation | $821.00M | $397.00M | $592.00M | $584.00M | $521.00M |
| Change in Working Capital | $-20.18B | $-7.86B | $-13.91B | $-8.29B | $-7.54B |
| Accounts Receivables | $-8.05B | $-5.75B | $-17.01B | $2.08B | $-12.45B |
| Inventory | $-18.45B | $-2.65B | $-5.33B | $-9.88B | $-1.49B |
| Accounts Payables | $- | $5.75B | $17.01B | $-2.08B | $12.45B |
| Other Working Capital | $6.32B | $-5.20B | $-8.59B | $1.59B | $-6.05B |
| Other Non Cash Items | $-21.92B | $-21.96B | $-2.69B | $2.29B | $6.35B |
| Net Cash Provided by Operating Activities | $45.43B | $58.87B | $28.11B | $35.70B | $29.84B |
| Investments in Property Plant and Equipment | $-16.40B | $-18.86B | $-19.05B | $-12.56B | $-6.12B |
| Acquisitions Net | $-12.00M | $- | $-326.00M | $-15.51B | $1.27B |
| Purchases of Investments | $-145.49B | $-136.17B | $-88.97B | $-75.42B | $-111.92B |
| Sales Maturities of Investments | $129.78B | $112.81B | $77.77B | $79.53B | $111.70B |
| Other Investing Activities | $-8.16B | $859.00M | $4.19B | $1.30B | $137.00M |
| Net Cash Used for Investing Activities | $-40.28B | $-41.37B | $-26.39B | $-22.66B | $-4.92B |
| Debt Repayment | $-1.15B | $-1.01B | $2.73B | $-697.00M | $-19.16B |
| Common Stock Issued | $805.00M | $368.00M | $334.00M | $269.00M | $4.00M |
| Common Stock Repurchased | $- | $- | $- | $-1.19B | $-474.00M |
| Dividends Paid | $-6.65B | $-4.98B | $-4.15B | $-4.15B | $-3.92B |
| Other Financing Activities | $3.23B | $-21.23B | $-1.34B | $5.47B | $-2.21B |
| Net Cash Used Provided by Financing Activities | $-3.76B | $-26.86B | $-2.42B | $-298.00M | $-25.16B |
| Effect of Forex Changes on Cash | $-59.00M | $286.00M | $733.00M | $113.00M | $-25.00M |
| Net Change in Cash | $1.33B | $-9.07B | $32.00M | $12.86B | $-266.00M |
| Cash at End of Period | $7.11B | $5.78B | $14.85B | $14.82B | $1.96B |
| Cash at Beginning of Period | $5.78B | $14.85B | $14.82B | $1.96B | $2.23B |
| Operating Cash Flow | $45.43B | $58.87B | $28.11B | $35.70B | $29.84B |
| Capital Expenditure | $-27.43B | $-18.86B | $-19.05B | $-12.56B | $-6.12B |
| Free Cash Flow | $18.00B | $40.01B | $9.06B | $23.14B | $23.73B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $14.04B | $13.41B | $13.92B | $13.07B | $13.79B | $14.80B | $14.03B | $25.01B | $12.47B | $11.13B | $11.88B | $875.00M | $7.07B | $9.92B | $5.71B | $5.54B | $198.00M | $7.62B | $5.79B | $7.64B |
| Depreciation and Amortization | $4.72B | $3.98B | $3.81B | $3.71B | $3.77B | $3.79B | $3.57B | $3.06B | $3.27B | $3.13B | $3.05B | $2.96B | $2.98B | $2.98B | $2.90B | $3.17B | $3.22B | $3.27B | $3.14B | $2.96B |
| Deferred Income Tax | $4.70B | $5.75B | $4.90B | $2.95B | $4.47B | $4.33B | $4.44B | $3.66B | $3.88B | $4.98B | $2.78B | $1.61B | $2.64B | $2.76B | $1.72B | $2.54B | $2.65B | $998.00M | $3.00B | $-500.00M |
| Stock Based Compensation | $103.00M | $107.00M | $101.00M | $97.00M | $99.00M | $103.00M | $108.00M | $21.00M | $113.00M | $117.00M | $146.00M | $141.00M | $161.00M | $143.00M | $147.00M | $129.00M | $151.00M | $161.00M | $143.00M | $122.00M |
| Change in Working Capital | $-9.65B | $-7.78B | $-13.14B | $-2.76B | $-11.86B | $2.61B | $-8.17B | $2.48B | $6.02B | $-9.78B | $-6.57B | $-1.55B | $6.66B | $-6.95B | $-12.07B | $1.86B | $-6.95B | $-2.63B | $-567.00M | $-3.40B |
| Accounts Receivables | $-7.85B | $-3.40B | $-786.00M | $-1.92B | $-8.83B | $7.34B | $-4.65B | $2.49B | $1.91B | $-3.71B | $-6.44B | $-4.14B | $6.16B | $-7.55B | $-11.48B | $3.65B | $-3.19B | $-2.04B | $3.66B | $-5.95B |
| Inventory | $-1.06B | $-5.01B | $-6.32B | $-3.90B | $-5.20B | $-4.70B | $-4.64B | $-4.21B | $-284.00M | $2.77B | $-926.00M | $-1.06B | $25.00M | $1.07B | $-5.36B | $-1.10B | $-3.17B | $-1.95B | $-3.65B | $2.68B |
| Accounts Payables | $- | $- | $- | $- | $8.83B | $-7.34B | $4.65B | $-2.49B | $-1.91B | $3.71B | $6.44B | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $-737.00M | $620.00M | $-6.03B | $4.55B | $-6.65B | $7.31B | $-3.54B | $6.69B | $6.31B | $-12.55B | $-5.65B | $-485.00M | $6.63B | $-8.02B | $-6.71B | $2.97B | $-3.78B | $-680.00M | $3.08B | $-6.08B |
| Other Non Cash Items | $-7.30B | $-6.15B | $-1.09B | $-54.00M | $-5.53B | $-7.71B | $-2.72B | $-14.55B | $-2.49B | $-289.00M | $-4.62B | $5.09B | $-2.17B | $-3.76B | $-1.85B | $-1.97B | $5.01B | $-166.00M | $-592.00M | $-4.28B |
| Net Cash Provided by Operating Activities | $6.62B | $9.32B | $8.50B | $11.52B | $4.74B | $17.93B | $11.25B | $19.68B | $23.26B | $9.28B | $6.66B | $9.12B | $17.33B | $5.11B | $-3.45B | $11.27B | $4.27B | $9.25B | $10.91B | $2.55B |
| Investments in Property Plant and Equipment | $-7.20B | $-7.54B | $-5.11B | $-6.28B | $-5.04B | $-3.94B | $-12.17B | $-3.75B | $-3.10B | $-3.33B | $-8.69B | $-4.03B | $-4.47B | $-7.21B | $-3.34B | $-3.20B | $-4.79B | $-2.67B | $-1.89B | $-2.10B |
| Acquisitions Net | $- | $- | $- | $- | $5.04B | $3.94B | $12.17B | $- | $- | $- | $- | $-326.00M | $- | $3.63B | $137.00M | $15.30B | $1.93B | $-524.00M | $-14.99B | $602.00M |
| Purchases of Investments | $-54.08B | $-76.59B | $-61.74B | $-40.31B | $-35.17B | $-40.40B | $-29.61B | $-48.46B | $-40.70B | $-19.87B | $-27.14B | $-48.20B | $-10.67B | $-11.57B | $-18.52B | $-16.54B | $-7.94B | $-16.91B | $-34.02B | $-19.11B |
| Sales Maturities of Investments | $56.31B | $115.72B | $47.27B | $34.77B | $23.20B | $38.65B | $33.16B | $36.19B | $17.22B | $28.75B | $30.64B | $30.19B | $12.09B | $19.54B | $15.96B | $10.12B | $16.11B | $18.62B | $34.67B | $13.08B |
| Other Investing Activities | $-485.00M | $-50.67B | $-668.00M | $-6.11B | $-4.22B | $-2.77B | $-11.79B | $248.00M | $169.00M | $180.00M | $262.00M | $380.00M | $298.00M | $-416.00M | $160.00M | $-15.12B | $-1.54B | $238.00M | $509.00M | $-643.00M |
| Net Cash Used for Investing Activities | $-5.46B | $-19.07B | $-20.25B | $-11.35B | $-16.18B | $-4.52B | $-8.24B | $-15.77B | $-26.41B | $5.73B | $-4.92B | $-21.99B | $-2.76B | $3.97B | $-5.61B | $-9.45B | $3.76B | $-1.25B | $-15.72B | $-8.17B |
| Debt Repayment | $1.52B | $16.55B | $10.27B | $- | $- | $- | $-991.00M | $-4.13B | $-199.00M | $-7.07B | $-10.29B | $5.40B | $-176.00M | $-202.00M | $2.46B | $-189.00M | $-7.19B | $-2.06B | $1.75B | $5.77B |
| Common Stock Issued | $25.00M | $7.19B | $19.00M | $31.00M | $9.00M | $686.00M | $79.00M | $221.00M | $81.00M | $35.00M | $31.00M | $8.00M | $45.00M | $134.00M | $147.00M | $20.00M | $72.00M | $85.00M | $92.00M | $1.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00B | $- | $-190.00M | $- | $- |
| Dividends Paid | $- | $-6.66B | $- | $- | $- | $-6.65B | $- | $- | $- | $-4.98B | $- | $- | $- | $-4.15B | $- | $-4.13B | $- | $-4.15B | $- | $-602.00M |
| Other Financing Activities | $-956.00M | $-937.00M | $-744.00M | $-564.00M | $5.27B | $-1.07B | $-564.00M | $-389.00M | $701.00M | $-331.00M | $-541.00M | $-313.00M | $-2.44B | $-3.00B | $-342.00M | $13.94B | $-436.00M | $-2.25B | $5.33B | $-331.00M |
| Net Cash Used Provided by Financing Activities | $590.00M | $16.15B | $9.54B | $-533.00M | $5.28B | $-7.04B | $-1.48B | $-4.30B | $583.00M | $-12.35B | $-10.80B | $5.10B | $-2.57B | $-7.21B | $2.26B | $8.64B | $-7.55B | $-8.56B | $7.18B | $5.44B |
| Effect of Forex Changes on Cash | $-5.00M | $-23.00M | $17.00M | $-65.00M | $161.00M | $-66.00M | $-89.00M | $-88.00M | $-267.00M | $128.00M | $513.00M | $648.00M | $-6.00M | $-51.00M | $142.00M | $43.00M | $57.00M | $-55.00M | $68.00M | $-95.00M |
| Net Change in Cash | $1.75B | $6.37B | $-2.19B | $-428.00M | $-6.00B | $6.31B | $1.45B | $-480.00M | $-2.83B | $2.80B | $-8.55B | $-7.12B | $12.00B | $1.81B | $-6.65B | $10.50B | $533.00M | $-612.00M | $2.44B | $-282.00M |
| Cash at End of Period | $13.03B | $11.29B | $4.91B | $7.11B | $7.54B | $13.54B | $7.23B | $5.78B | $6.26B | $9.09B | $6.30B | $14.85B | $21.98B | $9.98B | $8.17B | $14.82B | $4.32B | $3.79B | $4.40B | $1.96B |
| Cash at Beginning of Period | $11.29B | $4.91B | $7.11B | $7.54B | $13.54B | $7.23B | $5.78B | $6.26B | $9.09B | $6.30B | $14.85B | $21.98B | $9.98B | $8.17B | $14.82B | $4.32B | $3.79B | $4.40B | $1.96B | $2.24B |
| Operating Cash Flow | $6.62B | $9.32B | $8.50B | $11.52B | $4.74B | $17.93B | $11.25B | $19.68B | $23.26B | $9.28B | $6.66B | $9.12B | $17.33B | $5.11B | $-3.45B | $11.27B | $4.27B | $9.25B | $10.91B | $2.55B |
| Capital Expenditure | $-8.82B | $-7.91B | $-6.42B | $-6.28B | $-5.04B | $-3.94B | $-12.17B | $-3.75B | $-3.10B | $-3.33B | $-8.69B | $-4.03B | $-4.47B | $-7.21B | $-3.34B | $-3.20B | $-4.79B | $-2.67B | $-1.89B | $-2.10B |
| Free Cash Flow | $-2.20B | $1.41B | $2.07B | $5.24B | $-305.00M | $13.99B | $-921.00M | $15.93B | $20.16B | $5.95B | $-2.04B | $5.09B | $12.86B | $-2.10B | $-6.79B | $8.06B | $-522.00M | $6.58B | $9.02B | $449.00M |
Dr. Reddy's Laboratories Dividends
Explore Dr. Reddy's Laboratories's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
3.19%
Dividend Payout Ratio
11.94%
Dividend Paid & Capex Coverage Ratio
1.33x
Dr. Reddy's Laboratories Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $2.3959 | $0.47917 | July 30, 2024 | July 15, 2024 | August 12, 2024 | May 09, 2024 |
| $2.4383 | $0.48767 | July 28, 2023 | July 10, 2023 | August 11, 2023 | May 11, 2023 |
| $0.488 | $0.0976 | July 07, 2023 | July 10, 2023 | January 02, 2024 | May 11, 2023 |
| $1.89 | $0.378 | August 01, 2022 | July 11, 2022 | August 12, 2022 | May 24, 2022 |
| $0.387 | $0.0774 | July 08, 2022 | July 11, 2022 | July 11, 2022 | May 24, 2022 |
| $0.2797 | $0.0559482 | July 30, 2021 | July 09, 2021 | August 11, 2021 | |
| $1.7097 | $0.34194 | July 08, 2021 | July 09, 2021 | August 11, 2021 | June 16, 2021 |
| $0.274 | $0.066 | July 10, 2020 | July 13, 2020 | August 17, 2020 | June 26, 2020 |
| $0.287 | $0.0574 | July 12, 2019 | July 15, 2019 | August 15, 2019 | |
| $0.297 | $0.0594 | July 13, 2018 | July 16, 2018 | August 09, 2018 | |
| $1.55 | $0.31 | July 13, 2017 | July 17, 2017 | August 10, 2017 | June 06, 2017 |
| $1.485 | $0.297 | July 14, 2016 | July 18, 2016 | August 09, 2016 | June 06, 2016 |
| $1.56 | $0.312 | July 08, 2015 | August 17, 2015 | ||
| $1.515 | $0.303 | August 01, 2014 | August 15, 2014 | ||
| $0.264 | $0.0528 | July 10, 2013 | August 15, 2013 | ||
| $0.229 | $0.0458 | June 27, 2012 | August 06, 2012 | ||
| $1.255 | $0.251 | June 29, 2011 | August 11, 2011 | ||
| $3.26 | $0.652 | June 14, 2011 | |||
| $1.2 | $0.24 | June 30, 2010 | |||
| $0.655 | $0.131 | July 02, 2009 |
Dr. Reddy's Laboratories News
Read the latest news about Dr. Reddy's Laboratories, including recent articles, headlines, and updates.
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.
Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection.
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range.
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chief Executive Officer M V Narasimham – Chief Financial Officer Conference Call Participants Kunal Dhamesha – Macquarie Neha Manpuria – Bank of America Amey Chalke – JM Financial Bino Pathiparampil – Elara Capital Surya Narayan Patra – PhillipCapital Damayanti Kerai – HSBC Tushar Manudhane – Motilal Oswal Financial Services Saion Mukherjee – Nomura Foram Parekh – Bank of Baroda Capital Market Anubhav Agrawal – UBS Vishal Manchanda – Systematix Shashank Krishnakumar – Emkay Global Operator Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Amey Chalke - JM Financial Mikaela Franceschina - Barclays Harith Ahmad - Avendus Spark Damayanti Kerai - HSBC Bino Pathiparampil - Elara Capital Surya Patra - PhillipCapital Tarang Agarwal - Old Bridge Kunal Randeria - Axis Capital Anubhav Agarwal - UBS Vishal Manchanda - Systematix Operator Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science.
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma.
Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value.
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business.
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for RDY.